Search results for " Metastases"

showing 10 items of 100 documents

Natural history of malignant bone disease in renal cancer: final results of an Italian bone metastasis survey.

2013

BackgroundBone metastasis represents an increasing clinical problem in advanced renal cell carcinoma (RCC) as disease-related survival improves. There are few data on the natural history of bone disease in RCC.Patients and methodsData on clinicopathology, survival, skeletal-related events (SREs), and bone-directed therapies for 398 deceased RCC patients (286 male, 112 female) with evidence of bone metastasis were statistically analyzed.ResultsMedian time to bone metastasis was 25 months for patients without bone metastasis at diagnosis. Median time to diagnosis of bone metastasis by MSKCC risk was 24 months for good, 5 months for intermediate, and 0 months for poor risk. Median number of SR…

OncologyMaleAnatomy and PhysiologyBone diseaseEpidemiologySettore MED/06 - Oncologia Medicamedicine.medical_treatmentMetastasisMetastasisbone metastasesRenal cell carcinomaBasic Cancer ResearchMedicineMusculoskeletal SystemMultidisciplinaryDiphosphonatesrenal cell carcinoma bone metastasis zoledronic acidQRBone metastasisKidney NeoplasmsOncologyItalyObservational StudiesDisease ProgressionMedicineFemaleCancer Epidemiologymedicine.drugResearch Articlemedicine.medical_specialtyClinical Research DesignSciencerenal cancerBone NeoplasmsInternal medicineHumansBonerenal cancer; bone metastasesRetrospective Studiesbusiness.industryRenal Cell CarcinomaCancerCancers and NeoplasmsBone fracturemedicine.diseaseSurgeryRadiation therapyGenitourinary Tract TumorsZoledronic acidbusiness
researchProduct

Cetuximab plus FOLFOX-4 in untreated patients with advanced colorectal cancer: a Gruppo Oncologico dell'Italia Meridionale Multicenter phase II study.

2010

<i>Objectives:</i> FOLFOX-4 and FOLFIRI are considered equivalent in terms of activity and efficacy as first-line chemotherapy in metastatic colorectal cancer (mCRC). The monoclonal antibody (mAb) cetuximab showed intrinsic activity as a single agent in mCRC and was approved in combination with CPT-11 for patients who failed previous CPT-11-based treatment. The purpose of this phase II study was to evaluate the activity and safety of FOLFOX-4 plus cetuximab in untreated mCRC patients. <i>Methods:</i> Untreated patients with measurable metastatic disease and expressing epidermal growth factor receptor (EGFR) received cetuximab at a loading dose of 400 mg/m<sup>2…

OncologyMaleCancer ResearchLung NeoplasmsOrganoplatinum CompoundsSettore MED/06 - Oncologia MedicaColorectal cancerMetastaseLeucovorinPhases of clinical researchCetuximabColorectal Neoplasmmedicine.disease_causeMetastasisFOLFOXAntineoplastic Combined Chemotherapy ProtocolsProto-Oncogene ProteinFOLFOX-4CetuximabLiver NeoplasmsAntibodies MonoclonalGeneral MedicineMiddle AgedErbB ReceptorsColorectal carcinomaOncologyLiver NeoplasmFOLFIRIFemaleKRASFluorouracilColorectal NeoplasmsHumanmedicine.drugAdultProto-Oncogene Proteins B-rafmedicine.medical_specialtyAntibodies Monoclonal HumanizedBRAFProto-Oncogene Proteins p21(ras)Internal medicineProto-Oncogene ProteinsKRASmedicineHumansAgedAntineoplastic Combined Chemotherapy Protocolbusiness.industryOrganoplatinum CompoundCancerras Proteinmedicine.diseasedigestive system diseasesSurgeryLung NeoplasmMutationras ProteinsReceptor Epidermal Growth FactorbusinessBRAF; Cetuximab; Colorectal carcinoma; FOLFOX-4; KRAS; Metastases; Adult; Aged; Antibodies Monoclonal; Antibodies Monoclonal Humanized; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Mutation; Organoplatinum Compounds; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Receptor Epidermal Growth Factor; ras Proteins; Oncology; Cancer ResearchOncology
researchProduct

Predicting survival in node-positive prostate cancer after open, laparoscopic or robotic radical prostatectomy: A competing risk analysis of a multi-…

2016

Objectives: To investigate cancer-specific mortality and other-cause mortality in prostate cancer patients with nodal metastases. Methods: The study included 411 patients treated with radical prostatectomy and pelvic lymph node dissection for prostate cancer with lymph node metastases at 10 tertiary care centers between 1995 and 2014. Kaplan–Meier analyses were used to assess cancer-specific mortality-free survival rates at 8 years' follow up in the overall population, and after stratifying patients according to clinical and pathological parameters. Uni- and multivariable competing risk Cox regression analyses were used to assess cancer-specific mortality and other-cause mortality. Finally,…

OncologyMalemedicine.medical_treatment030232 urology & nephrologyProstate cancer0302 clinical medicineRobotic Surgical ProceduresLymph nodeeducation.field_of_studyProstatectomyMortality rateLymph NodePrognosiscancer-specific mortality competing risk analysis lymph node metastases other-cause mortality radical prostatectomylymph node metastaseDissectionmedicine.anatomical_structure030220 oncology & carcinogenesisLymphatic MetastasisLymphSurvival Analysicancer-specific mortality; competing risk analysis; lymph node metastases; other-cause mortality; radical prostatectomycancer-specific mortality; competing risk analysis; lymph node metastases; other-cause mortality; radical prostatectomy; Urologyother-cause mortalityHumanlymph node metastasesRiskmedicine.medical_specialtyRobotic Surgical ProcedurePrognosiUrologyPopulationUrologycancer-specific mortality03 medical and health sciencesInternal medicinemedicineHumanseducationcompeting risk analysiProstatectomybusiness.industryProportional hazards modelcompeting risk analysisProstatic NeoplasmsLymphatic MetastasiProstate-Specific Antigenmedicine.diseaseSurvival Analysisradical prostatectomyProstatic NeoplasmLymph Node ExcisionLaparoscopyLymph Nodesbusiness
researchProduct

New molecular targets in bone metastases.

2010

Bone metastases have a major impact on morbidity and on mortality in cancer patients. Despite its clinical relevance, metastasis remains the most poorly elucidated aspect of carcinogenesis. The biological mechanisms leading to bone metastasis establishment have been referred as " vicious circle," a complex network between cancer cells and the bone microenvironment. This review is aimed to underline the new molecular targets in bone metastases management other than bisphosphonates. Different pathways or molecules such as RANK/RANKL/OPG, cathepsin K, endothelin-1, Wnt/DKK1, Src have recently emerged as potential targets and nowadays preclinical and clinical trials are underway. The results fr…

Oncologymedicine.hormonemedicine.medical_specialtyPathologyCathepsin KProto-Oncogene Proteins pp60(c-src)Antineoplastic AgentsBone NeoplasmsBone NeoplasmAntibodies Monoclonal HumanizedEndothelinMetastasisAntineoplastic AgentEndothelinsBone metastases; Molecular targets; Animals; Antibodies Monoclonal; Antibodies Monoclonal Humanized; Antineoplastic Agents; Bone Neoplasms; Cathepsin K; Denosumab; Endothelins; Humans; Proto-Oncogene Proteins pp60(c-src); RANK Ligand; Medicine (all); Oncology; Radiology Nuclear Medicine and ImagingInternal medicineMedicineAnimalsHumansRadiology Nuclear Medicine and imagingMolecular targetbiologyAnimalbusiness.industryMedicine (all)EndothelinsRANK LigandCancerBone metastasisAntibodies MonoclonalGeneral Medicinemedicine.diseaseClinical trialBone metastaseDenosumabOncologyRANKLCancer cellbiology.proteinDenosumabbusinessHumanmedicine.drugCancer treatment reviews
researchProduct

Extranodal Extension of Nodal Metastases Is a Poor Prognostic Indicator in Gastric Cancer: a Systematic Review and Meta-analysis.

2016

Introduction: The extranodal extension (ENE) of nodal metastases (the extension of neoplastic cells through the nodal capsule into the perinodal soft tissue) is a histological feature that has been considered a prognostic factor in several cancers, but the role in gastric cancer was not yet investigated. We aimed to investigate the prognostic role of ENE in patients affected by gastric cancer through a systematic review and meta-analysis. Material and Methods: Two independent authors searched major databases until 09/30/2015 to identify studies providing data on gastric cancer patients’ prognostic parameters and comparing patients with ENE (ENE+) vs intra-nodal extension (ENE−). The data we…

Oncologymedicine.medical_specialty03 medical and health sciencesNodal Metastases Extranodal Extension Gastric Cancer0302 clinical medicineextranodal extension nodal metastases gastric cancerRecurrenceStomach NeoplasmsInternal medicineExtranodal extensionmedicineOdds RatioHumansGastric cancer . ENE . Extranodal extensionENE; Extranodal extension; Gastric cancer; Lymph node metastasis; Surgery; GastroenterologyProportional Hazards ModelsLymph node metastasisbusiness.industryProportional hazards modelNodal MetastasesHazard ratioConfoundingGastroenterologyCancerOdds ratiomedicine.diseasePrognosisConfidence interval030220 oncology & carcinogenesisMeta-analysisRelative riskLymphatic MetastasisENE030211 gastroenterology & hepatologySurgeryLymph NodesNeoplasm Recurrence LocalbusinessGastric cancerJournal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
researchProduct

Natural history of bone metastasis in colorectal cancer: final results of a large Italian bone metastases study.

2012

ABSTRACT Background Data are limited regarding bone metastases from colorectal cancer (CRC). The objective of this study was to survey the natural history of bone metastasis in CRC. Patients and methods This retrospective, multicenter, observational study of 264 patients with CRC involving bone examined cancer treatments, bone metastases characteristics, skeletal-related event (SRE) type and frequency, zoledronic acid therapy, and disease outcomes. Results Most patients with bone metastases had pathologic T3/4 disease at CRC diagnosis. The spine was the most common site involved (65%), followed by hip/pelvis (34%), long bones (26%), and other sites (17%). Median time from CRC diagnosis to b…

Oncologymedicine.medical_specialtyBone Density Conservation AgentSettore MED/06 - Oncologia MedicaColorectal cancerBone NeoplasmsColorectal NeoplasmBone Neoplasmdrug therapy/pathologyZoledronic AcidInternal medicinemedicineHumansImidazolePelvisRetrospective Studiesdrug therapy/secondarybone metastases colorectal cancer zoledronic acidBone Density Conservation AgentsDiphosphonatesbusiness.industryImidazolesBone metastasisCancerRetrospective cohort studyHematologymedicine.diseaseNatural historyBone Density Conservation AgentsZoledronic acidmedicine.anatomical_structureDiphosphonateOncologytherapeutic useBone Density Conservation Agents; therapeutic use; Bone Neoplasms; drug therapy/secondary; Colorectal Neoplasms; drug therapy/pathology; Diphosphonates; Humans; Imidazoles; Retrospective StudiesbusinessColorectal NeoplasmsHumanmedicine.drug
researchProduct

Treatment sequence of synchronously (liver) metastasized colon cancer

2016

No standards for staging, systemic therapy or the timing of an operation are defined for patients newly diagnosed with synchronous metastases and a primary in the colon. An expert group of radiologists, medical, radiation and surgical oncologists therefore came together to discuss staging and treatment sequence for these patients and came up with a recommendation based on current evidence of potential therapeutic options. The discussion was organized to debate recommendations centred on 5 topics and therefore the position paper is built upon these titles and their subtitles. Editrice Gastroenterologica Italiana S.r.l.

Oncologymedicine.medical_specialtyColonColorectal cancermedicine.medical_treatment030230 surgeryTreatment sequenceSystemic therapy03 medical and health sciencesLiver metastases0302 clinical medicinePharmacotherapyDrug TherapyInternal medicinemedicineHepatectomyHumansCombined Modality TherapyTreatment optionsNeoplasm StagingHepatologybusiness.industryGeneral surgeryLiver NeoplasmsGastroenterologyAntineoplastic Protocolsmedicine.diseaseCombined Modality TherapyExpert groupColorectal cancerLiver030220 oncology & carcinogenesisPosition paperHepatectomyColorectal NeoplasmsbusinessSynchronous presentation
researchProduct

GASTRIC METASTASES ORIGINATING FROM OCCULT BREAST LOBULAR CARCINOMA: DIAGNOSTIC AND THERAPEUTIC PROBLEMS

2008

Abstract Background Breast cancer is the most frequent malignant tumour to metastasize into the gastrointestinal tract in female and is second only to malignant melanoma. Nevertheless gastrointestinal metastases arising from breast cancer are quite rare. The upper gastrointestinal tract is more frequently involved and lobular infiltrating carcinoma has a greater predilection compared to the ductal type. Case presentation The authors describe the case of a 70 years old woman with a preoperative diagnosis of gastric undifferentiated medullary – type carcinoma, which was the first manifestation of an occult breast carcinoma. The primary site of carcinoma was identified with the use of a panel …

Oncologymedicine.medical_specialtyLobular carcinomalcsh:SurgeryBreast NeoplasmsCase Reportlcsh:RC254-282Fatal OutcomeBreast cancerStomach NeoplasmsSurgical oncologyInternal medicinemedicineCarcinomaHumansBREAST CANCER - GASTRIC METASTASESAgedbusiness.industryMelanomaCancerlcsh:RD1-811lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseOccultCarcinoma LobularSettore MED/18 - Chirurgia GeneraleOncologyFemaleSurgeryBreast carcinomabusiness
researchProduct

Secretory breast carcinoma with metastatic sentinel lymph node

2006

Abstract Background Secretory mammary carcinoma is a rare breast neoplasia originally described in children but sometimes also found in adults. It presents a more favourable outcome than more common histological types of breast carcinoma; published literature in fact reports only a few cases with axillary lymph node metastases and only four cases with distant metastases. Clinical presentation In this paper we report a rare case of secretory breast carcinoma with axillary lymph node metastases in a 33-year-old woman. To our knowledge, this is the first case of secretory carcinoma involving biopsy of the sentinel lymph node and investigation of the e-cadherin expression. We found positivity f…

Oncologymedicine.medical_specialtyPathologySentinel lymph nodelcsh:SurgeryCase ReportSettore MED/08 - Anatomia Patologicalcsh:RC254-282Mammary carcinomasentinel lymph nodeSurgical oncologyInternal medicinemedicineLymph nodebusiness.industrylcsh:RD1-811lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseSecretory breast carcinomaSettore MED/18 - Chirurgia GeneraleLymphedemamedicine.anatomical_structureSecretory breast carcinoma; sentinel lymph node; metastases; e-cadherinOncologymetastaseSurgerybusinessBreast carcinomae-cadherinSecretory Breast CarcinomaWorld Journal of Surgical Oncology
researchProduct

Gastric and Rectal Metastases from Malignant Melanoma Presenting with Hypochromic Anemia and Treated with Immunotherapy

2017

The authors present a case of an 80-year-old Caucasian male with multiple gastric and rectal metastases from malignant melanoma presenting with hypochromic anemia as the sole symptom of disease without evidence of cutaneous and ocular tumor localization. The patient had a medical history positive for malignant lentigo melanoma of the occipital region of the scalp and early stage laryngeal squamous cell carcinoma and prostatic carcinoma treated with radiation therapy. The authors make some considerations on intestinal involvement by metastatic melanoma and discuss the choice of not treating with endoscopic procedures the gastric metastatic lesions most likely responsible for the clinical sig…

Oncologymedicine.medical_specialtymedicine.medical_treatmentCase ReportIpilimumabPembrolizumablcsh:RC254-28203 medical and health sciences0302 clinical medicineInternal medicinemedicineCarcinomaMedical historyStage (cooking)business.industryMelanomalcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseDermatologyRadiation therapyHypochromic anemiaOncology030220 oncology & carcinogenesis030211 gastroenterology & hepatologybusinessmelanoma rectal metastases immunotherapymedicine.drugCase Reports in Oncological Medicine
researchProduct